In-vitro and in-vivo study of amorphous spironolactone prepared by adsorption method using supercritical CO2

Abstract Objective: The aim of this study was to improve the oral bioavailability of spironolactone (SP). Method: SP was adsorbed on the fumed silica using supercritical CO2 (scCO2) technology and further compressed into tablets. The morphology was observed by scanning electron microscopy (SEM), and the crystalline form was investigated by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). The dissolution test was performed in water, 0.1 M HCl solution, pH 4.5 acetate buffers and pH 6.8 phosphate buffers using the paddle method. The pharmacokinetics was undertaken in six dogs in a crossover fashion. Results: SP was successfully prepared into tablets and presented in amorphous state. SP-silica scCO2 tablets displayed higher dissolution profiles than SP-silica physical mixtures tablets in different media. The AUC0–t and Cmax of SP-silica supercritical CO2 was 1.61- and 1.52-fold greater than those of SP-silica physical mixtures (p < 0.05), respectively. Conclusion: It is a promising method in improving dissolution and bioavailability by adsorbing SP, a poorly soluble drug, on the fumed silica using rapid expansion of supercritical solutions.

[1]  C. Charcosset,et al.  Liposome preparation using a hollow fiber membrane contactor--application to spironolactone encapsulation. , 2011, International journal of pharmaceutics.

[2]  Ram B. Gupta,et al.  Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement. , 2011, Journal of pharmaceutical sciences.

[3]  Michael Türk,et al.  Formation of submicron poorly water-soluble drugs by rapid expansion of supercritical solution (RESS): Results for Naproxen , 2010 .

[4]  Hiroshi Nakao,et al.  Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  V. David,et al.  Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. , 2010, Journal of pharmaceutical and biomedical analysis.

[6]  Ram B. Gupta,et al.  Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  R. Tan,et al.  Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. , 2009, International journal of pharmaceutics.

[8]  M. Schneider,et al.  Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. , 2007, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

[9]  H. Suzuki,et al.  Solid dispersion of spironolactone with porous silica prepared by the solvent method. , 2007, Die Pharmazie.

[10]  Xing-gang Yang,et al.  Preparation of Budesonide-Poly (Ethylene Oxide) Solid Dispersions Using Supercritical Fluid Technology , 2007, Drug development and industrial pharmacy.

[11]  C. Charcosset,et al.  Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. , 2006, International journal of pharmaceutics.

[12]  Martial Sauceau,et al.  Particle generation for pharmaceutical applications using supercritical fluid technology , 2004 .

[13]  M. Kinoshita,et al.  Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. , 2002, Journal of pharmaceutical sciences.

[14]  K. Otake,et al.  Effects of supercritical impregnation conditions on the properties of silica–titania aerogels , 2001 .

[15]  Osama A. Soliman,et al.  Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability , 1997 .

[16]  H. Lamparczyk,et al.  Simultaneous determination of spironolactone and its metabolites in human plasma. , 1996, Journal of pharmaceutical and biomedical analysis.

[17]  S. Atkinson,et al.  Mineral excretion in premature infants receiving various diuretic therapies. , 1988, The Journal of pediatrics.

[18]  G. Mcinnes,et al.  Effect of Micronization on the Bioavailability and Pharmacologic Activity of Spironolactone , 1982, Journal of clinical pharmacology.

[19]  J. Clarke,et al.  Factors influencing comparative bioavailability of spironolactone tablets. , 1977, Journal of pharmaceutical sciences.

[20]  M. J. Cocero,et al.  Encapsulation and co-precipitation processes with supercritical fluids: Fundamentals and applications , 2009 .